Targeted delivery of small noncoding RNA for glioblastoma

Ji Young Yoo, Margaret Yeh, Balveen Kaur, Tae Jin Lee

Research output: Contribution to journalShort surveypeer-review

7 Scopus citations


Aberrant expression of certain genes and microRNAs (miRNAs) has been shown to drive cancer development and progression, thus the modification of aberrant gene and miRNA expression presents an opportunity for therapeutic targeting. Ectopic modulation of a single dysregulated miRNA has the potential to revert therapeutically unfavorable gene expression in cancer cells by targeting multiple genes simultaneously. Although the use of noncoding RNA-based cancer therapy is a promising approach, the lack of a feasible delivery platform for small noncoding RNAs has hindered the development of this therapeutic modality. Recently, however, there has been an evolution in RNA nanotechnology, in which small noncoding RNA is loaded onto nanoparticles derived from the pRNA-3WJ viral RNA motif of the bacteriophage phi29. Preclinical studies have shown the capacity of this technology to specifically target tumor cells by conjugating these nanoparticles with ligands specific for cancer cells and resulting in the endocytic delivery of siRNA and miRNA inhibitors directly into the cell. Here we provide a systematic review of the various strategies, which have been utilized for miRNA delivery with a specific focus on the preclinical evaluation of promising RNA nanoparticles for glioblastoma (GBM) targeted therapy.

Original languageEnglish (US)
Pages (from-to)274-280
Number of pages7
JournalCancer Letters
StatePublished - Mar 1 2021
Externally publishedYes


  • Glioblastoma
  • RNA nanoparticle
  • RNA nanotechnology
  • microRNA
  • siRNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeted delivery of small noncoding RNA for glioblastoma'. Together they form a unique fingerprint.

Cite this